Table 1.
Baseline Characteristics of the Cohort According to Bisphosphonate Use
| Characteristic | Nonuser(n = 82,035) |
Bisphosphonate User(n = 4,242) |
||||
|---|---|---|---|---|---|---|
| % | Mean | SD | % | Mean | SD | |
| Age, years | 64.5 | 7.1 | 67.7 | 6.5 | ||
| White race | 97.4 | 98.0 | ||||
| Body mass index (kg/m2) | 26.8 | 5.3 | 24.4 | 4.4 | ||
| Smoking | ||||||
| Never | 44.0 | 44.6 | ||||
| Previous/current | 56.0 | 55.6 | ||||
| Family history of colorectal cancer | 13.6 | 15.2 | ||||
| History of osteoporosis | 14.4 | 79.4 | ||||
| Regular aspirin use* | 45.5 | 48.1 | ||||
| Hormone replacement therapy | ||||||
| Premenopausal | 3.1 | 0.5 | ||||
| Never | 23.7 | 25.2 | ||||
| Previous/current | 73.2 | 74.3 | ||||
| Regular use of statin | 16.0 | 19.9 | ||||
| Total calcium intake (mg/d)† | 1,011 | 364 | 1,196 | 404 | ||
| Vitamin D intake (IU/d) | 437 | 271 | 536 | 295 | ||
| Folate intake (quantiles)† | 4.5 | 2.9 | 5.2 | 2.8 | ||
| Alcohol intake (g/d) | 4.9 | 9.1 | 4.9 | 8.6 | ||
| Physical activity (METs/wk) | 17.7 | 16.2 | 17.8 | 15.7 | ||
| History of polyps | 10.8 | 12.9 | ||||
| History of lower endoscopy | 32.7 | 42.3 | ||||
NOTE. Baseline information is based on 1998 questionnaire.
Abbreviations: SD, standard deviation; MET, metabolic equivalent.
*
Defined as ≥ two standard (325 mg) tablets per week.
†
Energy-adjusted intake from diet and supplements.